{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-22-000096","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.131189+00:00","generated_at":"2026-06-21T20:54:52.178285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Instil Bio Q3 net loss $56.2M; DELTA-1 trial paused; CMO resigns","bullets":["Q3 net loss $56.2M ($0.43/share); cash & securities $303.3M at Sept 30, down from $454.1M at Dec 31, 2021.","DELTA-1 trial voluntarily paused due to manufacturing contamination; FDA notified; update expected Q1 2023.","DELTA-2 enrollment deferred; first patient dosed with ITIL-306 (CoStAR-TIL) for NSCLC; clinical data expected in 2023.","Dr. Robert Hawkins appointed Head of R&D; Dr. Zachary Roberts resigned as CMO effective Nov 11, 2022.","Cash runway into 2025 expected with planned sale-leaseback of Tarzana manufacturing facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-22-000096","json":"https://secwatch.observer/filing/0001789769-22-000096.json","markdown":"https://secwatch.observer/filing/0001789769-22-000096.md","text":"https://secwatch.observer/filing/0001789769-22-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000096/0001789769-22-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000096/til-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:54:52.178285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2925351bfc8deb59a4f8fe8bae3498e281bd34c9","claim":"Instil Bio, Inc. reported the quarter ended September 30, 2022 results: EPS $ (0.43).","evidence_excerpt":"On November 14, 2022, Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000096/0001789769-22-000096-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"EPS","value":"$ (0.43)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}